TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02606734

Intervention type: DEVICE
Group type: OTHER
Intervention: Coronary Angiography
Description: The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
Study: NCT01646502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Esp protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard wound care
Study: NCT02702674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: propranolol 20 mg given before induction of labor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch tablet containing no active drug material given before induction of labor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: intravenous infusion of oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intravenous infusion of oxytocin
Study: NCT04526509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3901961
Description: GSK3901961 as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3901961
Description: GSK3901961 as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3845097
Description: GSK3845097 as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4427296
Description: GSK4427296 as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
Study: NCT03732677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti- PD-L1 Antibody
Study: NCT02297841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Novel lubricant Miami Fragrance
Study: NCT02003703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B Virus Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B Virus Vaccine
Study: NCT01687062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeSO4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeSO4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FeSO4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeSO4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeSO4

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reduction of phytate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reduction of phytate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaFeEDTA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Study: NCT01968278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked milk
Study: NCT01269606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin human
Description: At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin human
Description: At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
Study: NCT04427098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 Mg/0.4 mL Injectable Solution
Description: Subcutaneous enoxaparin 40 mg once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Subcutaneous enoxaparin for 14 days: 60 mg once daily in case of body weight of 45 to 60 kg; 80 mg once daily in case of weight from 61 to 100 kg; 100 mg once daily in case of bodyweight \>100 kg
Study: NCT02132260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftifine Hydrochloride Cream 2%
Description: Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naftin® (Naftifine Hydrochloride) Cream 2%
Description: Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Cream
Description: Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
Study: NCT06641596

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules of Placebo, once daily after breakfast for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cr-400
Description: 1 capsule of Cr-400 + 1 capsule of Placebo, once a day after breakfast for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cr-800
Description: 2 capsules of Cr-400, once a day after breakfast for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PE-500
Description: 1 capsule of PE + 1 capsule of Placebo, once a day after breakfast for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PE-1000
Description: 2 capsules of PE-500, once a day after breakfast for 12 weeks
Study: NCT03732677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy Agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy agent
Study: NCT04140097

Intervention type: OTHER
Intervention: Prospective monitoring of a large variety of parameters
Description: Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.

Intervention type: OTHER
Intervention: Prospective monitoring of a large variety of parameters
Description: Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
Study: NCT04540471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: MT group receives additional music therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: comprehensive in-patient education program
Description: comprehensive in-patient education program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive in-patient education program
Description: comprehensive in-patient education program
Study: NCT01416831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation therapy and high-dose IL-2
Description: Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose IL-2
Description: IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
Study: NCT00830336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Oral Suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax®
Description: Oral Suspension
Study: NCT01542944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TevaGastrim
Description: TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
Study: NCT02383823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogens
Description: Crossover study of estrogen or placebo in random order in menopausal women
Study: NCT04747639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 500 ml glucose-depleted apple juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 500 ml conventional apple juice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 250 ml glucose-depleted apple juice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 250 ml conventional apple juice
Study: NCT04195282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma exchange
Description: Patients will receive treatment of plasma exchange for three times in two weeks. The volume of fresh frozen plasma used in plasma exchange is about 2000 millilitre per time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RL-1 Novel Human-derived Bio-artificial Liver Treatment
Description: Patients will receive RL-1 Novel Human-derived Bio-artificial Liver treatment for three times in two weeks. The volume of plasma exchanged in the system is about 4000 millilitre per time.
Study: NCT03001882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT01386008

Intervention type: DEVICE
Group type: OTHER
Intervention: senfilcon A contact lens
Description: senofilcon A spherical contact lens worn in a daily wear modality

Intervention type: DEVICE
Group type: OTHER
Intervention: investigational enfilcon A
Description: investigational enfilcon A, worn daily wear modality
Study: NCT04449861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab plus chemotherapy
Description: Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria.~Drug: Carboplatin 4-6 cycles every 3 weeks~Drug: Cisplatin 4-6 cycles every 3 weeks~Drug: Etoposide 4-6 cycles every 3 weeks
Study: NCT02383823

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Crossover study of placebo or estrogen in random order in menopausal women
Study: NCT04201873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Tumor Cell Lysate Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic Cell Tumor Cell Lysate Vaccine
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poly ICLC
Description: Given IM
Study: NCT04034927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT04526158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile+Group LAMP Mindfulness-Based Intervention
Description: The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile LAMP Mindfulness-Based Intervention
Description: The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
Study: NCT03617939

Intervention type: PROCEDURE
Intervention: Biospeciman Collection
Description: Collection of blood, tissue, and other biological samples.

Intervention type: OTHER
Intervention: Survey Assessments
Description: Data taken from patient surveys and assessments, including quality of life.

Intervention type: OTHER
Intervention: Medical Chart Reviews
Description: Data taken directly from the patients' medical charts.
Study: NCT03349996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeStream Peripheral Stent Graft System
Description: Patients will be treated with the LifeStream Peripheral Stent Graft System
Study: NCT04637620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of MDD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Use of SSRI as an active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator
Study: NCT05115825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Attend Mobile Pain Coping Skills Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03315026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The M.D. Anderson Symptom Inventory (MDASI)
Description: assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
Study: NCT03952351

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT Coronary Angiography (CTCA)
Description: CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
Study: NCT03689179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time for Living and Caring (TLC)
Description: Time for Living \& Caring (TLC) is an online, self-administered intervention. It includes three types of modules: 1) virtual coaching module (defined as a series of prompts, reminders, and suggestions that guide caregivers through assessment, goal setting, and goal review activities) to monitor respite time-use and time-use goals, 2) an interactive calendar that can be used to schedule and track respite time, 3) resource pages (including links, printable forms, video guides) that provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time for Living and Caring (TLC)
Description: Time for Living \& Caring (TLC) is an online, self-administered intervention. It includes three types of modules: 1) virtual coaching module (defined as a series of prompts, reminders, and suggestions that guide caregivers through assessment, goal setting, and goal review activities) to monitor respite time-use and time-use goals, 2) an interactive calendar that can be used to schedule and track respite time, 3) resource pages (including links, printable forms, video guides) that provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?.
Study: NCT02900976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT02297841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Novel lubricant Miami no Fragrance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KY Liquid lubricant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astroglide Gel lubricant
Study: NCT01897987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumostem®